ECO Animal Health Group plc (LON:EAH - Get Free Report) insider David Hallas bought 15,500 shares of the company's stock in a transaction that occurred on Monday, December 2nd. The shares were bought at an average cost of GBX 74 ($0.94) per share, for a total transaction of £11,470 ($14,517.15).
ECO Animal Health Group Trading Up 1.4 %
EAH stock opened at GBX 73 ($0.92) on Tuesday. The company has a quick ratio of 2.14, a current ratio of 2.96 and a debt-to-equity ratio of 4.31. ECO Animal Health Group plc has a 52-week low of GBX 60 ($0.76) and a 52-week high of GBX 135 ($1.71). The company's 50-day simple moving average is GBX 74.68 and its 200-day simple moving average is GBX 101.87. The firm has a market cap of £49.45 million, a P/E ratio of 3,665.00 and a beta of -0.05.
Wall Street Analyst Weigh In
Separately, Shore Capital reiterated a "buy" rating on shares of ECO Animal Health Group in a research note on Friday.
View Our Latest Stock Analysis on EAH
ECO Animal Health Group Company Profile
(
Get Free Report)
Strange: Why is Amazon suddenly yielding 39.70%?
From Investors Alley | Ad
Something big is happening with Amazon stock…
While most investors collect ZERO dividends from Amazon…
A small group just discovered a "backdoor" way to collect yields up to 39.70%!
Click here to see this breakthrough before everyone else →
ECO Animal Health Group plc, together with its subsidiaries, develops, registers, and markets pharmaceutical products for animals worldwide. The company provides Aivlosin, a macrolide antibiotic for the treatment of enteric and respiratory diseases in pigs and poultry. It also offers generic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic, which are endectocides and other antiparasitics for the treatment and prevention of parasites, such as worms, ticks, mange, and lices in cattle, sheep, pigs, horses, and dogs; and Chlortetracycline and Oxytetracycline for treatment of bacterial infections in pigs, poultry, and cattle.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
